The clinical utility of lipid profile and positive troponin in predicting future cardiac events

Arun Kumar1*, Brijesh Sathian2

1Department of Biochemistry, International Medical School, Shah Alam Campus, Management and Science University, Malaysia
2Department of Community Medicine, Manipal College of Medical Sciences, Pokhara, Nepal

ARTICLE INFO

Article history:
Received 13 May 2011
Received in revised form 27 June 2011
Accepted 28 July 2011
Available online 28 February 2012

Keywords:
Troponin
Chest pain
Cardiac event
Lipid profile
TnI
TC
HDL
LDL

Abstract

Objective: To study the usefulness of traditional lipid profile levels in screening subjects who had developed chest pain due to cardiac event as indicated by a positive troponin I (TnI) test. Methods: In this retrospective study data of the 740 patients presented to the emergency department with symptoms of cardiac ischemia that underwent both troponin and lipid profiles tests were compared with the lipid profiles of 411 normal healthy subjects controls. The troponin was detected qualitatively when a specimen contains TnI above the 99th percentile (TnI >0.5 ng/mL). The total cholesterol (TC), high density lipoproteins (HDL), very low density lipoproteins (VLDL), and triacyl glycerol (TG) levels were also analyzed and low density lipoprotein level (LDL) was calculated using Friedewald’s formula. Results: Patients with chest pain and positive troponin test (with confirmed cardiac event) were found to have significantly elevated levels of TC, TG, LDL and significantly reduced HDL levels when compared to the patients who experienced only chest pain (negative troponin) and healthy controls. Conclusions: Traditional lipid profile levels still can be used in screening populations to identify the subjects with high risk of developing cardiac event which is identified by highly sensitive and specific positive troponin test.

1. Introduction

The assessment of patients with acute chest pain of possible cardiac cause continues to be a challenge and positive diagnosis has psychological, social and legal implications[1,2]. The presence of ST segment elevation in the electrocardiograph (ECG) is highly specific (but only about 50% sensitive[1]) for acute myocardial infarction (AMI). However, many patients presenting to coronary care units have chest pain without ST elevation in the ECG. The diagnostic possibilities in these cases include acute coronary syndrome in evolution, or ‘non–ischemic’ chest pain.

The World Health Organization defines for diagnosing AMI, the presence of two of the three enlisted features namely, symptoms of myocardial ischemia, elevated levels of cardiac marker (protein or enzyme) concentrations in the blood, and a typical electrocardiographic pattern involving the development of Q waves or persistent T wave changes[3]. Further the American Heart Association (AHA) case definition for AMI requires an “adequate set” of biomarkers: 2 measurements of the same marker at least 6 h interval[4-6].

Traditionally the cardiac enzymes used in the assessments for the detection of myocardial infarction (MI) include the triad of lactate dehydrogenase (LDH), aspartate transaminase [serum glutamate oxaloacetate transaminase (SGOT)], and creatine kinase–MB (CK–MB) which is of heart origin. However, the use of biochemical ‘gold–standard’ CK–MB levels has limited prognostic power[1,2] compared to the serum troponins (both I and T) which are considered to be more specific and sensitive over CK–MB in the setting of acute coronary syndromes and have been validated for post operative risk stratification for non–cardiac surgical procedures. With CK–MB being used as a
marker, it has limitations to identify the future risk of acute coronary syndromes. Hence, many of the patients are kept in ICCU and occupy beds unnecessarily, and others who are presumed to be safe and are discharged, return to ICCU with recurrent coronary events[1,2].

The assessment of smaller molecular mass proteins such as myoglobin (16 000 kD) derived from the cytosol of both skeletal and cardiac muscle, heart–type fatty acid binding protein (hFABP) which are considered to be more cardio specific, is promising for early detection of acute or persistent myocardial damage, however, in clinical practice neither of these proteins are considered as cardiac markers[3].

Highly sensitive and specific immunoassays for myocardial proteins, such as troponin T (TnT) and/or troponin I (TnI) which are components of the thin filaments of the sarcomere are used in the identification of subjects with small areas of myocardial necrosis[3].

The magnitude of troponin elevations has correlated with the risk of death and composite risk of death or non–fatal MI, irrespective of whether the patients had ST elevation or non–ST elevation acute coronary syndromes by observations of the recent studies[3].

TnI testing had better sensitivity, specificity and prognostic value than TnT testing. A positive TnI result was a strong predictor of cardiac events (death from cardiac causes or MI) in the next 30 days. The predictive value of a negative TnI result was also high, with a total 30-day event rate of 0.3%, regardless of the admission ECG[1,2].

The new diagnostic criteria include a characteristic rise and fall in blood concentrations of cardiac troponins and/or CK–MB in the context of spontaneous ischemic symptoms or coronary intervention[3]. Cardiac TnI and TnT are highly sensitive and highly specific and may be elevated when CK–MB concentrations are not even mildly elevated. In addition, they may predict recurrent cardiac events in patients with acute coronary syndromes. However, use of troponin testing has been limited by availability of laboratory–based diagnostic techniques and by relatively long processing times[1,2].

Even minor elevations of troponin concentrations in the blood are indicative of myocyte necrosis and not due to leakage of proteins through the myocyte cell membrane. The current immunoassays for TnT and TnI reliably detect cardiac (as distinct from skeletal muscle) forms of these proteins[3]. Furthermore, troponins have greater sensitivity and specificity for the diagnosis of MI in acute myocardial ischemia.

However, it is important to note that, some patients who were diagnosed of MI did not have elevated troponins or CK values[3]. Some patients had died even much before the cardiac markers reach the threshold for detection[3].

Further troponin concentrations are found to be elevated in tachycardia, percutaneous coronary intervention, pulmonary emboli with right ventricular infarction, cardiac surgery, myocarditis, and renal failure, in which the cause of myocyte necrosis is not known[3].

Therefore, in this study we are aimed to evaluate the association between lipid profile levels of the subjects with chest pain with positive or negative troponin test.

2. Materials and methods

In this retrospective study, the data of the registry maintained in the Department of Biochemistry of the Manipal Teaching Hospital, Pokhara, Nepal were analyzed. The WHO case definition[3] was used to retrospectively assign a diagnosis in 740 patients presenting to the emergency department with symptoms of cardiac ischemia. The inclusion criteria were the subjects (n=740) who were admitted to the intensive care unit of the hospital complaining severe chest pain and who were requested by the medical staff to get both troponin and lipid profiles done. In addition to that, reports of 411 healthy subjects who had got their lipid profiles checked using the medicare facility were assessed as controls.

The troponin was detected qualitatively when a specimen contains TnI above the 99th percentile (TnI>0.5 ng/mL) method[7-10]. The total cholesterol (TC), high density lipoproteins (HDL), very low density lipoproteins (VLDL), and triacyl glycerol (TG) levels were analyzed, using the kits provided by human diagnostics and the low density lipoprotein level (LDL) was calculated using Friedwald’s formula[11].

All the estimations were done using HUMAN 300 semi–auto analyzer and data were analyzed using Epi Info windows version. Significance of the difference of parameters among different groups was analyzed using Z–test.

The reports of the subjects with any of the missing data were excluded. The selection of the reports was done without the prior knowledge of both the subjects and the staff of the intensive care unit, so that healthcare workers and the study subjects were not influenced anyway during the study. Therefore, no written consent was obtained from any of the subjects. The ethical clearance was granted by the Ethical Committee of the Manipal College of Medical Sciences, Pokhara.

3. Results

Of the 740 subjects with the chest pain tested for the presence of troponin in the serum qualitatively, only 101 (13.6%) subjects were detected positive. The larger proportion of the subjects (86.4%) with severe chest pain was found to be troponin negative.

Initially, the differences in various lipid parameters among the subjects with chest pain and with or without a positive troponin test were compared (Table 1). In addition to that these two groups were compared for the same parameters
with those levels of normal healthy subjects (controls).

Significant difference was observed for age among the two groups of subjects (Table 1). However, except for HDL all other parameters of the lipid profiles were significantly different in two groups. Among the subjects with chest pain TC, TG, LDL levels were higher in the subjects with troponin positive than the subjects with a negative troponin. However, HDL level in the subjects with troponin positive were lower that that of the subjects with a negative troponin.

The data of Table 1 showed the comparison of biochemical data of the subjects with chest pain and with or without a positive test for troponin against the healthy controls.

Of the subjects with chest pain, a significantly ($P<0.001$) higher levels of VLDL and TG, were observed in subjects with positive troponin test, when compared to the healthy subjects (Table 1) and the subjects with a negative troponin test (Table 1).

However, HDL level of the subjects with chest pain and positive troponin was significantly ($P<0.001$) lower than that of controls (Table 1) and the subjects with a negative troponin test (Table 1).

The effect of sex on having only chest pain (when troponin is negative) was evaluated and data were given in Table 1. In the subjects with chest pain which is not due to cardiac event as indicated by negative troponin test, non significant differences were observed for all the parameters in males versus females. However, all these parameters were within the normal levels.

### 4. Discussion

In a previous study of subjects with chest pain it was reported that troponin was positive in 160 subjects (31.9%) and negative in 323 (64.3%) subjects[4-6]. They also reported higher incidence of AMI, acute heart failure, and death due to cardiac event in the subjects with chest pain and positive troponin confirming that it is a powerful, independent and valuable tool for risk stratification in patients with acute chest pain. Our data indicated that, of the subjects with chest pain (740) only 101 subjects (13.6%) were detected positive and a larger proportion of subjects (86.4%) were detected negative for troponin. Accordingly, those one hundred one subjects with chest pain are at high risk of developing cardiac event though the incidence of cardiac event is lower (13.6%).

It is well known that increased levels of LDL, TG and TC and decreased levels of HDL are also indicative of increased incidence of cardiac events and are considered as risk factors[6]. Therefore, in this retrospective study the relationship between levels of lipid profile parameters and the results of troponin test in predicting cardiac events was evaluated.

The mean TC level of the subjects with positive troponin (186.78±32.14) was slightly below the recommended desirable level (<200 mg/dL)[12] thus indicating those subjects are susceptible to develop cardiac event. The level of TC of the subjects with negative troponin test but with chest pain (179.04±28.94) was significantly lower than that of the subjects with positive troponin above confirming the importance of maintaining TC level below the recommended level[12].

Similarly, the mean TG level of the subjects with positive troponin (186.14±36.95) was well above both the recommended desirable level[12] (<150 mg/dL) and the level of TG of the subjects with negative troponin test but with chest pain (177.28±44.65). Further the TG level of the subjects with only chest pain was slightly higher than the recommended safe level.

Increased level of LDL is highly atherogenic as it could get oxidized and initiates the atheroma formation. Thus it is believed that increased level of LDL than the recommended level is a high risk factor in the development of cardiac event. The mean LDL level of the subjects with positive troponin (186.14±36.95) was well above both the recommended level (108.91±30.07) was well below the recommended desirable level (<130 mg/dL)[12]. Further the mean LDL level of the subjects with negative troponin test but with chest pain (177.28±44.65) was significantly lower than that of the subjects with positive troponin above confirming the importance of maintaining lower levels of LDL in preventing future cardiac event.

Thus our data indicated that the subjects who developed chest pain due to cardiac event as confirmed by positive troponin test had significantly greater levels of TC, TG, LDL when compared to those levels in subjects without cardiac event as indicated by negative troponin test.

On the other hand, lower HDL level (<40 mg/dL) is also regarded as a cardiac risk factor[12] and the mean HDL level

### Table 1

Comparison of lipid profiles of the subjects with chest pain and with and without positive troponin against healthy controls (mean±SD).

| Variables          | Control (n=411) | Subjects with chest pain (n=740) | Troponin positive (n=101) | Troponin negative (n=639) | Males (n=373) | Females (n=266) |
|--------------------|-----------------|---------------------------------|---------------------------|---------------------------|---------------|-----------------|
| Age (years)        | 54.81±13.76     | 65.51±10.94*                    | 61.07±14.24***            | 60.61±14.40              | 61.72±14.02   | 61.72±14.02     |
| TC (mg/dL)         | 181.36±47.59    | 186.78±32.14^Δ                  | 179.04±28.94              | 178.34±31.35             | 180.02±25.20  | 180.02±25.20    |
| TG (mg/dL)         | 147.48±66.88    | 186.14±36.95***                 | 177.28±44.65***           | 177.33±45.20             | 177.21±43.96  | 177.21±43.96    |
| LDL (mg/dL)        | 105.61±41.00    | 108.91±30.07^Δ                  | 100.32±38.04*             | 101.28±43.33             | 98.97±29.08   | 98.97±29.08     |
| HDL (mg/dL)        | 42.80±10.50     | 41.06±2.58**                    | 41.39±6.45*               | 41.35±6.12               | 41.45±6.69    | 41.45±6.69      |
| VLDL (mg/dL)       | 29.44±13.12     | 37.46±7.30***                   | 35.82±8.92***             | 35.79±9.02               | 35.86±8.80    | 35.86±8.80      |

* P<0.05, **: P<0.01, ***: P<0.001, troponin positive and troponin negative groups compared with control group; ^Δ: P<0.001, troponin positive group compared with troponin negative group.
of the subjects with positive troponin (41.06±2.58) was in the recommended safe level. This also indicates that the development of cardiac event was associated with reduced levels of HDL than the recommended level. Further the subjects with negative troponin test (no cardiac event) had a mean HDL level above the cut off value suggestive of safe levels and that value was (41.39±6.45) significantly \( P=0.360 \) greater than the mean HDL levels of the subjects who had a cardiac event.

These lipid parameters were also compared with the values of aged matched 411 healthy subjects without any known disease condition. All the values of lipid parameters are within the safe levels for healthy subjects indicating they were having a minimum possibility of developing any cardiac event.

The TC and LDL levels of the subjects with positive troponin were significantly \( P<0.001 \) greater than the healthy subjects and no significant difference was observed for TC between healthy subjects and subjects with a negative troponin test but with chest pain. However, no significant differences were observed for TG and VLDL between these groups.

Significantly lower \( P=0.003 \) mean HDL level was observed in the subjects with positive troponin when compared to healthy subjects and the subjects only with chest pain but with negative troponin test.

These data indicated that the chest pain due to cardiac event as determined by positive troponin test is closely associated with elevated levels of TC, LDL, TG and also with significantly reduced HDL. However, the comparison of lipid parameters of males and females in the sub group of negative troponin tests revealed that there were no major significant differences of those parameters due to differences in sex.

Therefore, our data clearly show that patients who developed chest pain due to cardiac event as confirmed by positive troponin test had lipid parameters in the risk levels as suggested by ATP III[12]. Therefore, the subjects who had lipid profile levels within risk level were at a greater risk of developing chest pain due to cardiac event. Thus it is advisable to screen and identify subjects with risk levels of lipid profile parameters and advise them to control their lipid profiles to maintain within the levels as recommended[12].

Secondly, the data also confirm that patients with chest pain due to cardiac event can be confirmed by lipid profile as these values correspond to troponin positive patients with chest pain due to cardiac events. In a set up where troponin test cannot be done, the chest pain due to cardiac events can be confirmed by assessing lipid profile in those patients.

Acknowledgments

We acknowledged the Ethical Clearance Committee and the CEO and Dean of Manipal College of Medical Sciences for granting us the approval to carry out this study.

References

[1] De Silva LD, Kumar A, Sathian B. The significance of lipid profile and positive troponin in predicting cardiac event. Kathmandu Univ Med J (KUMJ) 2009; 7(3): 263–267.
[2] Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American college of cardiology/American heart association task force on practice guidelines. Circulation 2008; 117: 296–329.
[3] Sodi R. Cardiac troponins: clinical and analytical aspects. Adv Clin Chem 2006; 41: 49–122.
[4] Macrae AR, Kavsak PA, Lustig V, Bhargava R, Vandersluis R, Palomaki GE, et al. Assessing the requirement for the 6 hour interval between specimens in the American Heart Association Classification of Myocardial Infarction in Epidemiology and Clinical Research Studies. Clin Chem 2006; 52(5): 812–818.
[5] Alpert JS. Will the real myocardial infarction please stand up? Clin Chem 2006; 52(5): 795–796.
[6] Alpert JS, Thygesen K, Jaffe A, White HD. The universal definition of myocardial infarction; a consensus document: ischaemic heart disease. Heart 2008; 94(10): 1335–1341.
[7] Bonaca M, Scirica B, Sabatine M, Dalling A, Spinar J, Murphy AS, et al. Prospective evaluation of the prognostic implications of improved assay performance with a sensitive assay for cardiac troponin I. J Am Coll Cardiol 2010; 55(19): 2218–2124.
[8] Giuseppe L, Gianfranco C. High-sensitivity troponin T concentrations in acute chest pain patients evaluated with cardiac computed tomography. Circulation 2011; 123: e3.
[9] Mills NL, Churchhouse AM, Lee KK, Anand A, Gamble D, Shah AS, et al. Implementation of a sensitive troponin I assay and risk of recurrent myocardial infarction and death in patients with suspected acute coronary syndrome. JAMA 2011; 305(12): 1210–1216.
[10] Jaffe AS, Lindahl B, Katus HA. Sensitive troponin I assay in patients with suspected acute coronary syndrome. JAMA 2011; 306(5): 488–489.
[11] Fridewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultra centrifuge. Clin Chem 1972; 18: 499–502.
[12] Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 2002; 106: 3143–3421.

Conflict of interest statement

We declare that we have no conflict of interest.